Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - AMGEN INC | d385954d8k.htm |
Exhibit 99.1
|
||
| One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com | ||
| News Release |
AMGEN’S SECOND QUARTER 2012 REVENUES
INCREASED 13 PERCENT TO $4.5 BILLION AND
ADJUSTED EARNINGS PER SHARE (EPS)
INCREASED 34 PERCENT TO $1.83
2012 Total Revenues and Adjusted EPS Guidance Ranges Increased
to $16.9-$17.2 Billion and $6.20-$6.35
Second Quarter 2012 GAAP EPS Increased 29 Percent to $1.61
THOUSAND OAKS, Calif. (July 26, 2012) – Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2012. Key results for the quarter include:
| • | Total revenues increased 13 percent to $4,477 million, with 8 percent product sales growth driven by strong performance across the portfolio. |
| • | Amgen modified its agreement with Takeda to grant exclusive worldwide development rights for motesanib, recognizing income of $206 million in other revenues. |
| • | Adjusted EPS grew 34 percent to $1.83 due to 23 percent adjusted operating income growth and lower shares outstanding. Adjusted net income increased 12 percent to $1,433 million. |
| • | GAAP EPS increased 29 percent to $1.61 and GAAP net income increased 8 percent to $1,266 million. |
| • | Amgen generated approximately $2.2 billion of free cash flow. |
| • | Four AMG 145 Phase 2 studies have successfully completed and the Company plans to initiate Phase 3 development in early 2013. |
“I am very pleased with the performance of the business in the first half,” said Bob Bradway, CEO at Amgen. “I am excited about the growth opportunities in our research and development pipeline, particularly our biologic AMG 145 for hypercholesterolemia.”
| Year-Over-Year (YOY) | ||||||||||||
| $Millions, except EPS and percentages | Q2 ‘12 | Q2 ‘11 | YOY D | |||||||||
| Total Revenue |
$ | 4,477 | $ | 3,959 | 13 | % | ||||||
| Adjusted Net Income |
1,433 | 1,281 | 12 | % | ||||||||
| Adjusted EPS |
1.83 | 1.37 | 34 | % | ||||||||
| GAAP Net Income |
1,266 | 1,170 | 8 | % | ||||||||
| GAAP EPS |
$ | 1.61 | $ | 1.25 | 29 | % | ||||||
Adjusted EPS, adjusted operating income, adjusted net income, and free cash flow are non-GAAP financial measures. These adjustments and other items are presented on the attached reconciliations.
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 2
Product Sales Performance
| • | Total product sales increased 8 percent driven by strong commercial execution across the portfolio. |
| • | Combined Neulasta® (pegfilgrastim) and NEUPOGEN® (Filgrastim) sales grew 2 percent driven mainly by an increase in the U.S. average net sales price. |
| • | Combined U.S. Neulasta and NEUPOGEN sales increased 6 percent driven by increases in the average net sales price and unit demand, offset partially by a decrease in wholesaler inventories. |
| • | Combined Neulasta and NEUPOGEN sales in the rest of the world (ROW) declined 13 percent due to a decrease in NEUPOGEN unit demand from loss of share to biosimilars and a decrease in the average net sales price of Neulasta and NEUPOGEN. |
| • | Enbrel® (etanercept) sales increased 11 percent driven primarily by an increase in the average net sales price, as well as increases in unit demand and wholesaler inventories. |
| • | Aranesp® (darbepoetin alfa) sales decreased 8 percent driven primarily by a decline in unit demand. |
| • | U.S. sales decreased 11 percent driven primarily by a decline in unit demand, offset partially by a change in accounting estimates and an increase in the average net sales price. |
| • | ROW sales decreased 7 percent driven primarily by a decrease in the average net sales price. |
| • | EPOGEN® (epoetin alfa) sales decreased 3 percent driven by a reduction in dose utilization, offset largely by reductions in customer discounts and a change in accounting estimates. |
| • | On a sequential basis, EPOGEN sales increased 18 percent driven by customer and wholesaler buying patterns. There was a low single-digit percentage point growth in underlying unit demand. |
| • | Growth-phase products: Sensipar®/Mimpara® (cinacalcet), Vectibix® (panitumumab), and Nplate® (romiplostim) increased 15 percent driven by higher unit demand. |
| • | Momentum for both XGEVA® (denosumab) and Prolia® (denosumab) continued in the second quarter with solid sequential growth. |
| • | XGEVA sales increased 17 percent on a sequential basis, reflecting increased segment share as well as growth in the overall skeletal-related events segment. |
| • | Prolia sales increased 36 percent on a sequential basis, reflecting continued unit growth globally. |
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 3
Product Sales Detail by Product and Geographic Region
| $Millions, except percentages | Q2 ‘12 | Q2 ‘11 | YOY D | |||||||||||||||||
| US | ROW | TOTAL | TOTAL | TOTAL | ||||||||||||||||
|
Neulasta® / NEUPOGEN® |
$ | 1,062 | $ | 285 | $ | 1,347 | $ | 1,326 | 2 | % | ||||||||||
|
Neulasta® |
794 | 221 | 1,015 | 1,015 | 0 | % | ||||||||||||||
|
NEUPOGEN® |
268 | 64 | 332 | 311 | 7 | % | ||||||||||||||
|
Enbrel® |
991 | 67 | 1,058 | 956 | 11 | % | ||||||||||||||
|
Aranesp® |
215 | 321 | 536 | 585 | (8 | %) | ||||||||||||||
|
EPOGEN® |
525 | 0 | 525 | 543 | (3 | %) | ||||||||||||||
|
Sensipar® / Mimpara® |
150 | 82 | 232 | 199 | 17 | % | ||||||||||||||
|
Vectibix® |
31 | 59 | 90 | 81 | 11 | % | ||||||||||||||
|
Nplate® |
50 | 36 | 86 | 75 | 15 | % | ||||||||||||||
|
XGEVA® |
156 | 23 | 179 | 73 | * | |||||||||||||||
|
Prolia® |
75 | 45 | 120 | 44 | * | |||||||||||||||
| Other |
0 | 27 | 27 | 11 | * | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Total product sales |
$ | 3,255 | $ | 945 | $ | 4,200 | $ | 3,893 | 8 | % | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| * | Not meaningful |
Other Revenues
| • | Other revenues increased to $277 million in the second quarter of 2012 versus $66 million in the second quarter of 2011, driven by changes to the Company’s motesanib collaboration with Takeda Pharmaceutical Company Limited. As part of efforts to focus its research and development (R&D) activities, in the second quarter the Company replaced the global co-development and profit share agreement with an exclusive license for Takeda to develop, manufacture and commercialize motesanib. This resulted in revenue recognition of $206 million from an upfront payment received from Takeda when the collaboration was originally formed in 2008. |
Operating Expense and Tax Rate Analysis, on an Adjusted Basis
| • | Cost of Sales, excluding the impact of the Puerto Rico excise tax, increased 0.4 points to 13.9 percent of sales driven primarily by product mix, offset partially by higher average net sales prices and lower royalties. |
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 4
| • | R&D expenses were flat. Expenses in support of our later-stage clinical programs increased, driven by AMG 145 and AMG 785. This increase was offset by reduced expenses associated with marketed product support and Discovery Research and Translational Sciences. |
| • | Selling, General & Administrative (SG&A) expenses increased 8 percent driven primarily by international expansion as well as higher ENBREL profit share expenses. |
| • | ENBREL profit share expenses increased 11 percent to $371 million in the second quarter. |
| $Millions, except percentages On an Adjusted Basis |
Q2 ‘12 | Q2 ‘11 | YOY D | |||||||||
| Cost of Sales |
$ | 668 | $ | 569 | 17 | % | ||||||
| % of sales |
15.9 | % | 14.6 | % | 1.3 | pts. | ||||||
| % of sales (Excluding PR excise tax) |
13.9 | % | 13.5 | % | 0.4 | pts. | ||||||
| Research & Development (R&D) |
$ | 807 | $ | 808 | 0 | % | ||||||
| % of sales |
19.2 | % | 20.8 | % | (1.6 | ) pts. | ||||||
| Selling, General & Administrative (SG&A) |
$ | 1,199 | $ | 1,111 | 8 | % | ||||||
| % of sales |
28.5 | % | 28.5 | % | 0 | pts. | ||||||
| TOTAL Operating Expenses |
$ | 2,674 | $ | 2,488 | 7 | % | ||||||
|
pts: percentage points |
||||||||||||
| • | Tax Rate increased by 0.8 points to 16.0 percent due primarily to the expiry of the U.S. federal R&D tax credit at the end of 2011. As of June 30, 2012, the R&D tax credit had not been extended. |
| On an Adjusted Basis | Q2 ‘12 | Q2 ‘11 | YOY D | |||||||||
| Tax Rate |
16.0 | % | 15.2 | % | 0.8 | pts. | ||||||
| Tax Rate (Excluding PR excise tax) |
20.6 | % | 20.3 | % | 0.3 | pts. | ||||||
|
pts: percentage points |
||||||||||||
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 5
Cash Flow and Balance Sheet Discussion
| • | The Company generated $2.2 billion of free cash flow in the quarter versus $1.4 billion in the second quarter of 2011. The increase was primarily driven by the termination of fixed to floating interest rate swap agreements that resulted in receipt of $0.4 billion in cash, and by the collection of $0.2 billion of outstanding trade receivables in Spain. The termination of the swap agreements will be recognized as a reduction of interest expense over the remaining term of the underlying contracts and did not materially impact income in the quarter. |
| • | During the quarter, Amgen repurchased approximately 17 million shares of common stock at a total cost of $1.2 billion at an average price of $69.31. This brings the total shares repurchased under its $10 billion authorized stock repurchase program to 122 million at a total cost of $7.6 billion at an average price of $62.75. |
| • | During the quarter, the Company raised an additional $3 billion in U.S. bonds with an average maturity of 15 years and an average pre-tax coupon of 3.6 percent, and now has adequate funding to complete its $10 billion share repurchase program. |
| • | The Company previously announced that its Board of Directors declared a $0.36 per share dividend for the third quarter of 2012. The dividend will be paid on Sept. 7, 2012, to all stockholders of record as of the close of business on Aug. 16, 2012. |
| $Billions, except shares | Q2 ‘12 | Q2 ‘11 | YOY D | |||||||||
| Operating Cash Flow |
$ | 2.4 | $ | 1.5 | $ | 0.9 | ||||||
| Capital Expenditures |
0.2 | 0.1 | 0.1 | |||||||||
| Free Cash Flow |
2.2 | 1.4 | 0.8 | |||||||||
| Dividend Paid |
0.3 | 0.0 | 0.3 | |||||||||
| Cost of Shares Repurchased |
1.2 | 0.7 | 0.5 | |||||||||
| Adjusted Avg. Diluted Shares (millions) |
784 | 934 | (150 | ) | ||||||||
| Cash Balance |
22.5 | 19.2 | 3.3 | |||||||||
| Adjusted Debt Outstanding |
24.5 | 14.2 | 10.3 | |||||||||
| Stockholders’ Equity |
19.2 | 25.6 | (6.4 | ) | ||||||||
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 6
2012 Guidance
For the full year 2012, the Company now expects:
| • | Total revenues to be in the range of $16.9 billion to $17.2 billion and adjusted EPS to be in the range of $6.20 to $6.35. |
The Company continues to expect:
| • | Adjusted tax rate to be in the range of 14 percent to 15 percent. Excluding the Puerto Rico excise tax, Amgen still expects the adjusted tax rate for 2012 to be in the range of 19 percent to 20 percent. |
| • | Capital expenditures to be approximately $700 million. |
Second Quarter Pipeline Update
The Company provided the following information on selected clinical programs:
| • | AMG 145: The Company announced that in four Phase 2 studies (evaluating AMG 145 as monotherapy, in combination with statin therapy, in heterozygous familial hypercholesterolemia, and in statin-intolerant subjects), treatment with AMG 145 resulted in a statistically significant reduction in low-density lipoprotein (LDL) cholesterol. Based on the Phase 2 efficacy and safety data, the Company plans to initiate Phase 3 development in early 2013. |
| • | Rilotumumab (AMG 102): The Company discussed Phase 2 data showing that the addition of rilotumumab to chemotherapy improved median overall survival in subjects with gastric tumors with high expression of the hepatocyte growth factor receptor, MET. Phase 3 planning is underway. |
| • | AMG 785: The Company stated that it was enrolling a second Phase 3 study (alendronate-controlled) to evaluate safety and efficacy of AMG 785 in women with postmenopausal osteoporosis. |
| • | KAI Pharmaceuticals: The Company discussed the completion of the acquisition of KAI Pharmaceuticals on July 5, 2012. Phase 3 planning is underway for the lead molecule, KAI-4169. |
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 7
Non-GAAP Financial Measures
The Adjusted non-GAAP (U.S. Generally Accepted Accounting Principles) financial measures included above for the second quarters of 2012 and 2011 exclude, for the applicable periods, certain expenses related to acquisitions and cost-savings initiatives, non-cash interest expense associated with our convertible notes and certain other adjustments, as applicable. These adjustments and other items are presented on the attached reconciliations.
Management has presented its operating results in accordance with GAAP and on an “adjusted” (or non-GAAP) basis for the second quarters of 2012 and 2011. In addition, management has presented its outstanding debt in accordance with GAAP and on an “adjusted” (or non-GAAP) basis as of June 30, 2012 and 2011. The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.
Forward-Looking Statements
This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2011, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company’s results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others’ regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 8
impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock.
CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)
###
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 9
Amgen Inc.
Condensed Consolidated Statements of Income - GAAP
(In millions, except per share data)
(Unaudited)
| Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| Revenues: |
||||||||||||||||
| Product sales |
$ | 4,200 | $ | 3,893 | $ | 8,101 | $ | 7,511 | ||||||||
| Other revenues |
277 | 66 | 424 | 154 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenues |
4,477 | 3,959 | 8,525 | 7,665 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating expenses: |
||||||||||||||||
| Cost of sales (excludes amortization of certain acquired intangible assets presented below) |
682 | 602 | 1,361 | 1,166 | ||||||||||||
| Research and development |
826 | 819 | 1,562 | 1,555 | ||||||||||||
| Selling, general and administrative |
1,228 | 1,130 | 2,304 | 2,153 | ||||||||||||
| Amortization of certain acquired intangible assets |
73 | 73 | 147 | 147 | ||||||||||||
| Other |
79 | 3 | 85 | 19 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
2,888 | 2,627 | 5,459 | 5,040 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating income |
1,589 | 1,332 | 3,066 | 2,625 | ||||||||||||
| Interest expense, net |
256 | 122 | 491 | 257 | ||||||||||||
| Interest and other income, net |
124 | 129 | 248 | 277 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income before income taxes |
1,457 | 1,339 | 2,823 | 2,645 | ||||||||||||
| Provision for income taxes |
191 | 169 | 373 | 350 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income |
$ | 1,266 | $ | 1,170 | $ | 2,450 | $ | 2,295 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Earnings per share: |
||||||||||||||||
| Basic |
$ | 1.63 | $ | 1.26 | $ | 3.13 | $ | 2.47 | ||||||||
| Diluted |
$ | 1.61 | $ | 1.25 | $ | 3.09 | $ | 2.45 | ||||||||
| Average shares used in calculation of earnings per share: |
||||||||||||||||
| Basic |
776 | 927 | 783 | 930 | ||||||||||||
| Diluted |
785 | 935 | 792 | 938 | ||||||||||||
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 10
Amgen Inc.
Product Sales Detail by Product and Geographic Region
(In millions)
(Unaudited)
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
|
Neulasta® - U.S |
$ | 794 | $ | 769 | $ | 1,608 | $ | 1,479 | ||||||||
|
NEUPOGEN® - U.S |
268 | 230 | 507 | 450 | ||||||||||||
|
Neulasta® - ROW |
221 | 246 | 446 | 472 | ||||||||||||
|
NEUPOGEN® - ROW |
64 | 81 | 130 | 157 | ||||||||||||
|
Enbrel® - U.S |
991 | 894 | 1,869 | 1,715 | ||||||||||||
|
Enbrel® - Canada |
67 | 62 | 127 | 116 | ||||||||||||
|
Aranesp® - U.S |
215 | 241 | 417 | 491 | ||||||||||||
|
Aranesp® - ROW |
321 | 344 | 637 | 674 | ||||||||||||
|
EPOGEN® - U.S |
525 | 543 | 971 | 1,078 | ||||||||||||
|
Sensipar® - U.S |
150 | 124 | 290 | 240 | ||||||||||||
|
Mimpara® - ROW |
82 | 75 | 161 | 146 | ||||||||||||
|
Vectibix® - U.S |
31 | 31 | 62 | 61 | ||||||||||||
|
Vectibix® - ROW |
59 | 50 | 118 | 95 | ||||||||||||
|
Nplate® - U.S |
50 | 40 | 104 | 77 | ||||||||||||
|
Nplate® - ROW |
36 | 35 | 72 | 63 | ||||||||||||
|
XGEVA® - U.S |
156 | 73 | 295 | 115 | ||||||||||||
|
XGEVA® - ROW |
23 | — | 37 | — | ||||||||||||
|
Prolia® - U.S |
75 | 30 | 129 | 47 | ||||||||||||
|
Prolia® - ROW |
45 | 14 | 79 | 24 | ||||||||||||
| Other - ROW |
27 | 11 | 42 | 11 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total product sales |
$ | 4,200 | $ | 3,893 | $ | 8,101 | $ | 7,511 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| U.S |
$ | 3,255 | $ | 2,975 | $ | 6,252 | $ | 5,753 | ||||||||
| ROW |
945 | 918 | 1,849 | 1,758 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total product sales |
$ | 4,200 | $ | 3,893 | $ | 8,101 | $ | 7,511 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 11
Amgen Inc.
Condensed Consolidated Balance Sheets - GAAP
(In millions)
(Unaudited)
| June 30, 2012 |
December 31, 2011 |
|||||||
| Assets |
||||||||
| Current assets: |
||||||||
| Cash, cash equivalents and marketable securities |
$ | 22,475 | $ | 20,641 | ||||
| Trade receivables, net |
2,708 | 2,896 | ||||||
| Inventories |
2,592 | 2,484 | ||||||
| Other current assets |
1,787 | 1,572 | ||||||
|
|
|
|
|
|||||
| Total current assets |
29,562 | 27,593 | ||||||
| Property, plant and equipment, net |
5,437 | 5,420 | ||||||
| Intangible assets, net |
3,470 | 2,584 | ||||||
| Goodwill |
12,428 | 11,750 | ||||||
| Other assets |
1,329 | 1,524 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 52,226 | $ | 48,871 | ||||
|
|
|
|
|
|||||
| Liabilities and Stockholders’ Equity |
||||||||
| Current liabilities: |
||||||||
| Accounts payable and accrued liabilities |
$ | 5,616 | $ | 5,670 | ||||
| Current portion of long-term debt |
2,416 | 84 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
8,032 | 5,754 | ||||||
| Long-term debt |
21,962 | 21,344 | ||||||
| Other non-current liabilities |
2,993 | 2,744 | ||||||
| Stockholders’ equity |
19,239 | 19,029 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 52,226 | $ | 48,871 | ||||
|
|
|
|
|
|||||
| Shares outstanding |
769 | 796 | ||||||
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 12
Amgen Inc.
GAAP to “Adjusted” Reconciliations
(In millions)
(Unaudited)
| Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| GAAP cost of sales |
$ | 682 | $ | 602 | $ | 1,361 | $ | 1,166 | ||||||||
| Adjustments to cost of sales: |
||||||||||||||||
| Incremental expense resulting from accelerating depreciation and/or accruing losses for facility operating leases as a result of our transaction with Boehringer Ingelheim involving our Fremont, California manufacturing facility |
(11 | ) | (23 | ) | (21 | ) | (44 | ) | ||||||||
| Acquisition-related expenses |
— | (7 | ) | — | (7 | ) | ||||||||||
| Stock option expense (a) |
(3 | ) | (3 | ) | (6 | ) | (6 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total adjustments to cost of sales |
(14 | ) | (33 | ) | (27 | ) | (57 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted cost of sales |
$ | 668 | $ | 569 | $ | 1,334 | $ | 1,109 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP research and development expenses |
$ | 826 | $ | 819 | $ | 1,562 | $ | 1,555 | ||||||||
| Adjustments to research and development expenses: |
||||||||||||||||
| Acquisition-related expenses |
(13 | ) | (1 | ) | (20 | ) | (25 | ) | ||||||||
| Stock option expense (a) |
(6 | ) | (10 | ) | (12 | ) | (19 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total adjustments to research and development expenses |
(19 | ) | (11 | ) | (32 | ) | (44 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted research and development expenses |
$ | 807 | $ | 808 | $ | 1,530 | $ | 1,511 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP selling, general and administrative expenses |
$ | 1,228 | $ | 1,130 | $ | 2,304 | $ | 2,153 | ||||||||
| Adjustments to selling, general and administrative expenses: |
||||||||||||||||
| Acquisition-related expenses |
(22 | ) | (6 | ) | (34 | ) | (8 | ) | ||||||||
| Stock option expense (a) |
(7 | ) | (13 | ) | (14 | ) | (23 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total adjustments to selling, general and administrative expenses |
(29 | ) | (19 | ) | (48 | ) | (31 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted selling, general and administrative expenses |
$ | 1,199 | $ | 1,111 | $ | 2,256 | $ | 2,122 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP operating expenses |
$ | 2,888 | $ | 2,627 | $ | 5,459 | $ | 5,040 | ||||||||
| Adjustments to operating expenses: |
||||||||||||||||
| Adjustments to cost of sales |
(14 | ) | (33 | ) | (27 | ) | (57 | ) | ||||||||
| Adjustments to research and development expenses |
(19 | ) | (11 | ) | (32 | ) | (44 | ) | ||||||||
| Adjustments to selling, general and administrative expenses |
(29 | ) | (19 | ) | (48 | ) | (31 | ) | ||||||||
| Non-cash amortization of product technology rights acquired in a prior year business combination |
(73 | ) | (73 | ) | (147 | ) | (147 | ) | ||||||||
| Certain charges (or the reversal of certain previously over-accrued charges) pursuant to our continuing efforts to improve cost efficiencies in our operations |
(69 | ) | 5 | (70 | ) | (11 | ) | |||||||||
| Expense resulting from changes in the estimated fair values of the contingent consideration obligations related to a prior year business combination |
(1 | ) | (3 | ) | (3 | ) | (3 | ) | ||||||||
| Expense related to certain legal proceedings |
(9 | ) | (5 | ) | (12 | ) | (5 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total adjustments to operating expenses |
(214 | ) | (139 | ) | (339 | ) | (298 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted operating expenses |
$ | 2,674 | $ | 2,488 | $ | 5,120 | $ | 4,742 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP operating income |
$ | 1,589 | $ | 1,332 | $ | 3,066 | $ | 2,625 | ||||||||
| Adjustments to operating expenses |
214 | 139 | 339 | 298 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted operating income |
$ | 1,803 | $ | 1,471 | $ | 3,405 | $ | 2,923 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP income before income taxes |
$ | 1,457 | $ | 1,339 | $ | 2,823 | $ | 2,645 | ||||||||
| Adjustments to income before income taxes: |
||||||||||||||||
| Adjustments to operating expenses |
214 | 139 | 339 | 298 | ||||||||||||
| Non-cash interest expense associated with our convertible notes |
35 | 32 | 69 | 76 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total adjustments to income before income taxes |
249 | 171 | 408 | 374 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted income before income taxes |
$ | 1,706 | $ | 1,510 | $ | 3,231 | $ | 3,019 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP provision for income taxes |
$ | 191 | $ | 169 | $ | 373 | $ | 350 | ||||||||
| Adjustments to provision for income taxes: |
||||||||||||||||
| Income tax effect of the above adjustments (b) |
82 | 60 | 138 | 125 | ||||||||||||
| Income tax benefit related to certain prior period charges excluded from “Adjusted” earnings |
— | — | — | 5 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total adjustments to provision for income taxes |
82 | 60 | 138 | 130 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted provision for income taxes |
$ | 273 | $ | 229 | $ | 511 | $ | 480 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| GAAP net income |
$ | 1,266 | $ | 1,170 | $ | 2,450 | $ | 2,295 | ||||||||
| Adjustments to income before income taxes, net of the tax effect of the above adjustments |
167 | 111 | 270 | 249 | ||||||||||||
| Income tax benefit related to certain prior period charges excluded from “Adjusted” earnings |
— | — | — | (5 | ) | |||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Adjusted net income |
$ | 1,433 | $ | 1,281 | $ | 2,720 | $ | 2,539 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 13
Amgen Inc.
GAAP to “Adjusted” Reconciliations
(In millions, except per share data)
(Unaudited)
The following table presents the computations for GAAP and “Adjusted” diluted EPS, computed under the treasury stock method.
“Adjusted” EPS presented below excludes stock option expense:
| Three months ended June 30, 2012 |
Three months ended June 30, 2011 |
|||||||||||||||
| GAAP | “Adjusted” | GAAP | “Adjusted” | |||||||||||||
| Income (Numerator): |
||||||||||||||||
| Net income for basic and diluted EPS |
$ | 1,266 | $ | 1,433 | $ | 1,170 | $ | 1,281 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Shares (Denominator): |
||||||||||||||||
| Weighted-average shares for basic EPS |
776 | 776 | 927 | 927 | ||||||||||||
| Effect of dilutive securities |
9 | 8 | (*) | 8 | 7 | (*) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares for diluted EPS |
785 | 784 | 935 | 934 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted EPS |
$ | 1.61 | $ | 1.83 | $ | 1.25 | $ | 1.37 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Six months ended June 30, 2012 |
Six months ended June 30, 2011 |
|||||||||||||||
| GAAP | “Adjusted” | GAAP | “Adjusted” | |||||||||||||
| Income (Numerator): |
||||||||||||||||
| Net income for basic and diluted EPS |
$ | 2,450 | $ | 2,720 | $ | 2,295 | $ | 2,539 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Shares (Denominator): |
||||||||||||||||
| Weighted-average shares for basic EPS |
783 | 783 | 930 | 930 | ||||||||||||
| Effect of dilutive securities |
9 | 8 | (*) | 8 | 7 | (*) | ||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted-average shares for diluted EPS |
792 | 791 | 938 | 937 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted earnings per share |
$ | 3.09 | $ | 3.44 | $ | 2.45 | $ | 2.71 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| (*) | Dilutive securities used to compute “Adjusted” diluted EPS for the three and six months ended June 30, 2012 and 2011 were computed under the treasury stock method assuming that we do not expense stock options. |
| (a) | For the three and six months ended June 30, 2012 and 2011, the total pre-tax expense for employee stock options was $16 million and $32 million, respectively and $26 million and $48 million, respectively. |
“Adjusted” diluted EPS including the impact of stock option expense for the three and six months ended June 30, 2012 and 2011 was as follows:
| Three months ended June 30, |
Six months ended June 30, |
|||||||||||||||
| 2012 | 2011 | 2012 | 2011 | |||||||||||||
| “Adjusted” diluted EPS, excluding stock option expense |
$ | 1.83 | $ | 1.37 | $ | 3.44 | $ | 2.71 | ||||||||
| Impact of stock option expense (net of tax) |
(0.01 | ) | (0.02 | ) | (0.03 | ) | (0.04 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| “Adjusted” diluted EPS, including stock option expense |
$ | 1.82 | $ | 1.35 | $ | 3.41 | $ | 2.67 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| (b) | The tax effect of the adjustments between our GAAP and “Adjusted” results takes into account the tax treatment and related tax rate(s) that apply to each
adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including amortization of intangible assets and non-cash interest expense associated with our
convertible notes, whereas the tax impact of other adjustments, including stock option expense, depends on whether the amounts are deductible in the tax jurisdictions where the expenses are incurred or the asset is located and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three and six months ended June 30, 2012 and 2011 were 32.9% and 33.8% and 35.1% and 33.4%, respectively. |
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 14
Amgen Inc.
Reconciliation of GAAP Debt Outstanding to “Adjusted” Debt Outstanding
(In millions)
(Unaudited)
| GAAP | Adjustments for accounting standard (a) |
“Adjusted” | ||||||||||
| June 30, 2011 |
$ | 13,930 | $ | 221 | $ | 14,151 | ||||||
| June 30, 2012 |
$ | 24,378 | $ | 84 | $ | 24,462 | ||||||
| (a) | To exclude the impact of bifurcating the debt and equity components of our convertible notes as required by U.S. accounting standards for these securities commencing in 2009. |
Reconciliation of Free Cash Flow
(In millions)
(Unaudited)
| Three months ended June 30, |
||||||||
| 2012 | 2011 | |||||||
| Cash Flows from Operations |
$ | 2,375 | $ | 1,536 | ||||
| Capital Expenditures |
(172 | ) | (123 | ) | ||||
|
|
|
|
|
|||||
| Free Cash Flow |
$ | 2,203 | $ | 1,413 | ||||
|
|
|
|
|
|||||
Second Quarter 2012 Revenues Increased 13 Percent to $4.5 Billion and Adjusted
Earnings Per Share Increased 34 Percent to $1.83
Page 15
Amgen Inc.
Reconciliation of GAAP EPS Guidance to “Adjusted”
EPS Guidance for the Year Ending December 31, 2012
(Unaudited)
| 2012 | ||||||||||||||||
| GAAP EPS (diluted) guidance |
$ | 5.60 | - | $ | 5.76 | |||||||||||
| Known adjustments to arrive at “Adjusted” earnings*: |
||||||||||||||||
| Amortization of certain acquired intangible assets |
(a | ) | 0.24 | |||||||||||||
| Non-cash interest expense associated with our convertible notes |
(b | ) | 0.11 | |||||||||||||
| Charges associated with cost savings initiatives |
(c | ) | 0.10 | |||||||||||||
| Acquisition-related expenses |
(d | ) | 0.08 | |||||||||||||
| Stock option expense |
(e | ) | 0.06 | - | 0.05 | |||||||||||
| Legal settlements |
(f | ) | 0.01 | |||||||||||||
|
|
|
|||||||||||||||
| “Adjusted” EPS (diluted) guidance |
$ | 6.20 | - | $ | 6.35 | |||||||||||
|
|
|
|||||||||||||||
| * | The known adjustments are presented net of their related aggregate tax impact of approximately $0.31 to $0.32 per share. |
| (a) | To exclude the non-cash amortization of product technology rights acquired in a prior year business combination. |
| (b) | To exclude the non-cash interest expense associated with our convertible notes. |
| (c) | To exclude certain charges pursuant to our continuing efforts to improve cost efficiencies in our operations. |
| (d) | To exclude acquisition-related expenses. |
| (e) | To exclude stock option expense. |
| (f) | To exclude the expenses related to certain legal proceedings. |
Reconciliation of GAAP Tax Rate Guidance to “Adjusted”
Tax Rate Guidance for the Year Ending December 31, 2012
(Unaudited)
| 2012 with PR excise tax | 2012 without PR excise tax | |||||||||||||||||||||||
| GAAP tax rate guidance |
11.2 | % | - | 12.3 | % | 17.0 | % | - | 18.1 | % | ||||||||||||||
| Tax rate effect of known adjustments discussed above |
2.8 | % | - | 2.7 | % | 2.0 | % | - | 1.9 | % | ||||||||||||||
|
|
|
|
|
|||||||||||||||||||||
| “Adjusted” tax rate guidance |
14.0 | % | - | 15.0 | % | 19.0 | % | - | 20.0 | % | ||||||||||||||
|
|
|
|
|
|||||||||||||||||||||